FICHA DEL DOCTOR

Dr. José Maroto (web)

Publicaciones

Revistas científicas

Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populations. (ver web)

(coautor junto a Bellmunt J, Calvo E, García del Muro X, Climent MA, González-Larriba JL, Esteban E, López R, Paz-Ares L, Castellano D). Cancer Metast Rev 2010; 29(supl. 1): 11-20.

Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma. (ver web)

(coautor junto a Bellmunt J, Calvo E, García del Muro X, Climent MA, González-Larriba JL, Esteban E, López R, Paz-Ares L, Castellano D). Cancer Metast Rev 2010; 29(supl. 1): 1-10.

A Phase II trial of frist-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotheraphy. (ver web)

(coautor junto a Carles J, Bellmunt J, Trigo JM, Guillem V, López-Martín JA, Antón-Torres A, Urruticoechea L). SOGUG Study 06-01. Clin Transl Oncol. 2010 Jul; 12(7):503-8. 

First-line treatment with sunitinib monotherapy in patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapy: Pretreatment levels of IL8 and Hounsfield units as predictors of clinical benefit. (ver web)

J(coautor junto a Carles J, Bellmunt, JL González-Larriba, DE Castellano, B Mellado, E Gallardo, JL Pérez García, X Villanueva Sr., J Albanell). J Clin Oncol 28:15s 2010 (suppl; abstr 4540).